Bio News
Prolific Machines achieved a productivity of 21 g/L in monoclonal antibody (mAb) production, more than double the industry standard of 10 g/L. The company’s optogenetic platform directly controls gene expression in Chinese hamster ovary (CHO) cells with light during a 15-day process. The company is targeting 25 g/L by year-end and was recently designated an advanced technology by the U.S. Food and Drug Administration (FDA).
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
